Differentiation Assay
AML are characterized by blocked differentiation and an excessive accumulation of hematopoietic stem and/or progenitor cells. This is due to a variety of genetic errors that include aberrant expression of fusion oncoproteins, mutant myeloid transcriptor factors, mutant cytokine receptors, truncated granulocyte colony-stimulating factor receptor or unknown errors. The PharmaFlow platform allows the screening of drug candidates in AML patients, evaluating the potential differentiation capacity of blast cells adding a panel of terminal granulocytic or monocytic markers. Additional staining for cell viability (ie, Annexin-V) or normal populations (ie, Lymphocytes) contribute for the simultaneous analysis of both blast-maturation and toxicity, selecting those candidates with better effect and non-toxic profile.
Tubeandbracket
  • AML

Hematological
Sample

Cells 1

Mature
Myeloid
Cells

Cancer
Cells

Balance 1 Arrow

Native Cell Population:
Cancer Cells Prevalence

Cells 2

Mature
Myeloid
Cells

Cancer
Cells

Balance 2 Arrow

After Drug Incubation: Mature Myeloid Cells Prevalence

Plate

FCM
Readout

Differentiation Assay:
Native Environment

Differentiation Assay
Hematological
Sample
Tubeandbracket
  • AML
Native Cell Population: Cancer Cells Prevalence
Cells 1

Mature
Myeloid
Cells

Cancer
Cells

Balance 1 Arrow

After Drug Incubation: Mature Myeloid Cells Prevalence
Cells 2

Mature
Myeloid
Cells

Cancer
Cells

Balance 2 Arrow
FCM Readout
Plate
Differentiation Assay:
Native Environment
Differentiation Assay